Penelope Drake
Company: Catalent
Job title: Head of R&D, Bioconjugates
Seminars:
Live Discussion & Question Time 2:30 pm
day: Track B - Day 1 PM
Catalent’s SMARTag® Technology: Differentiated Solutions for Optimal ADCs 1:50 pm
SMARTag is a clinical-stage ADC technology featuring site-specific conjugation with multiple linker and warhead options. 6 CRs and 2 PRs among 22 patients were achieved by TRPH-222, a CD22-targeted SMARTag conjugate, in the dose-escalation stage of a Phase 1 trial for R/R B-cell lymphoma. We are using new linkers to achieve proprietary high DAR ADCs…Read more
day: Track B - Day 1 PM